Sweden Diabetes Market shall reach a value of US$ 1.86 billion in 2028, fuelled by factors such as increased prevalence, advancements in management and treatment options, and targeted healthcare initiatives

Renub Research has recently published a report named "Sweden Diabetes Market, Size, Forecast 2023-2028, Industry Trends, Growth, Impact of Inflation, Opportunity Company Analysis" providing a detailed industry analysis that consists of market share insights. Furthermore, the report studies competitors and regions and the recent Sweden Diabetes Market growth. Sweden Diabetes Market shall grow at a CAGR of 4.26% from 2023 to 2028. Diabetes significantly impacts the population of Sweden, with varying prevalence rates across the country. In Sweden, the number of individuals living with diabetes exceeds half a million, with a majority of them being affected by type 2 diabetes.

Expert Insights: Ask Analyst or Download Full Report with TOC & Figures: https://www.renub.com/sweden-diabetes-market-p.php

However, among Swedish children, type 1 diabetes prevails as the most prevalent chronic disease, with no current cure available. Southern and central regions like Stockholm, Gothenburg, and Malmö have higher rates, while the northern areas including Norrbotten, Västerbotten, and Jämtland have lower rates. According to a report published by the American Cancer Association, among adults aged 18 and above, there are 51,402 individuals with type 1 diabetes, 504,337 with type 2 diabetes, and 7,824,181 without a registered diabetes diagnosis or medication. Sweden has implemented strategies and initiatives for diabetes management and prevention, including education programs and accessible healthcare services, fuelling the rise of the Sweden diabetes market.

Technological advancements in Sweden have revolutionized diabetes management, with artificial pancreas systems, continuous glucose monitors (CGMs), and smart insulin pens leading the way. Artificial pancreas systems automate insulin delivery, enhancing control and reducing complications. CGMs provide real-time glucose measurements, enabling informed decisions for insulin dosing. Smart insulin pens, with smartphone connectivity, facilitate dose tracking and communication with healthcare providers. These innovations drive personalized care, propelling the Sweden diabetes market forward.

Digital health platforms and mobile apps like DiaCompanion, MySugr, Diabetes:Mia, and Tivolife assist individuals in monitoring blood sugar levels and self-management. These tools offer educational resources and support groups, empowering individuals and fostering growth in the Sweden diabetes market. Advancements in these areas contribute to improved treatment outcomes, disease control, and a better quality of life for people living with diabetes in Sweden.

Type 2 diabetes will gain increasing prominence in Sweden

Type 2 diabetes is expected to see a rise in prevalence in Sweden, reflecting a significant trend in the country's healthcare landscape. Unhealthy dietary habits, sedentary lifestyles, and an aging population contribute to the increasing number of cases. This growing prominence highlights the importance of implementing comprehensive preventive measures, early detection protocols, and effective management strategies.

Public health initiatives, education campaigns, and targeted healthcare interventions are crucial in addressing this health challenge and promoting healthier lifestyle choices. By prioritizing prevention, early intervention, and personalized care, Sweden can actively reduce the impact of type 2 diabetes and improve the overall health and well-being of its population. Additionally, Sweden also faces a notable incidence of Type 1 diabetes, particularly among children and young adults, influenced by genetic and environmental factors.

Swedish government has proactively implemented various initiatives to tackle and control diabetes

The Swedish government has implemented initiatives like the National Diabetes Plan, Register, and Education Program to improve diabetes care, track incidence, and provide support. These efforts have reduced diabetes prevalence, improved care quality, and supported research. The government also promotes healthy lifestyles and reduces smoking. They remain dedicated to ongoing efforts to combat diabetes and enhance the well-being of those affected.

Universal healthcare coverage in Sweden encompasses all residents, including those with diabetes, ensuring access to necessary treatment and supplies. The public health insurance system covers expenses related to diabetes care, such as insulin, blood glucose monitors, and essential supplies.

Report Details:

Convenience and effectiveness of SMBG is propelling the Self-monitoring of blood glucose (SMBG) segment in the Sweden diabetes market

SMBG is crucial in managing diabetes in Sweden, enabling individuals to monitor blood sugar levels and make informed decisions for their treatment and lifestyle. It promotes optimal blood sugar control, reducing complications and improving overall health. Notable SMBG devices in the country include the user-friendly Accu-Chek Aviva Plus blood glucose meter with a large display and ample storage capacity. The widely used FreeStyleLibre and Dexcom G6 continuous glucose monitors offer real-time analysis and alerts for high or low blood sugar levels, providing convenient and accurate monitoring. Sharing SMBG data with healthcare professionals enhances personalized care and collaborative decision-making.

Artificial intelligence (AI) is transforming SMBG device development, enhancing accuracy and usability. Implantable CGMs eliminate the need for finger pricks by continuously monitoring blood sugar levels, while closed-loop systems automatically adjust insulin doses based on real-time readings, offering individuals with diabetes more flexibility. These factors contribute to the growth and advancement of the SMBG segment in Sweden diabetes market.

Devices -The Sweden Diabetes Market breakup in 4 points

1. Continuous Glucose Monitoring (CGM)
2. Self-Monitoring Blood Glucose (SMBG)
3. Insulin Pen
4. Insulin Pump

Sweden Diabetes Market Sub-Segment Analysis

Continuous Glucose Monitoring (CGM)

1. Glucose Sensor Market & Forecast
2. CGM Transmitter Market & Forecast
3. Continuous Glucose Monitoring (CGM) User
4. CGM Reimbursement

SMBG

1. Test Strips Market and Forecast
2. Lancet Market and Forecast
3. Meter Market and Forecast
4. Blood Glucose (SMBG) Users
5. Blood Glucose Devices Reimbursement

Insulin Pen

1. Disposable Insulin Pen
2. Reusable Insulin Pen
3. Smart Insulin Pen
4. Insulin Pen Needle Market
5. Insulin Pen Users
6. Reimbursement Policies

Insulin Pump

1. Insulin Pump Market
2. Insulin Pump Users
3. Insulin Pump Products
4. Reimbursement Policies

Competitive Landscape

In the Sweden Diabetes Market, prominent competitors include B. Braun Melsungen AG, Eli Lilly Company, Terumo Corporation, Becton, Dickenson (BD), Novo Nordisk A/S, Ypsomed AG, Medtronic, Insulet Corporation, Abbott Laboratories, DarioHealth Corp., Dexcom Inc., Roche Diagnostic, and Tandem Diabetes Care.

Companies in the Report have been Studied from 3 Points

• Company Overview
• Recent Developments
• Financial Insight

Company Analysis

1. B. Braun Melsungen AG
2. Eli Lilly and Company
3. Terumo Corporation
4. Becton, Dickinson (BD)
5. Novo Nardisk
6. Ypsomed AG
7. Medtronic
8. InsuletCororation
9. Abbott Laboratories
10. DarioHealth Crop
11. Dexcom, Inc
12. Roche Diagnostic
13. Tandem Diabetes Care